DE69606324T2 - Verwendung von kernspinresonanz zur auffindung von liganden für bindungsmoleküle - Google Patents

Verwendung von kernspinresonanz zur auffindung von liganden für bindungsmoleküle

Info

Publication number
DE69606324T2
DE69606324T2 DE69606324T DE69606324T DE69606324T2 DE 69606324 T2 DE69606324 T2 DE 69606324T2 DE 69606324 T DE69606324 T DE 69606324T DE 69606324 T DE69606324 T DE 69606324T DE 69606324 T2 DE69606324 T2 DE 69606324T2
Authority
DE
Germany
Prior art keywords
ligand
target molecule
binding molecules
nuclear spin
spin resonance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69606324T
Other languages
English (en)
Other versions
DE69606324D1 (de
DE69606324T3 (de
Inventor
W Fesik
J Hajduk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24218250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69606324(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE69606324D1 publication Critical patent/DE69606324D1/de
Publication of DE69606324T2 publication Critical patent/DE69606324T2/de
Application granted granted Critical
Publication of DE69606324T3 publication Critical patent/DE69606324T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Iron (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
DE69606324T 1995-11-14 1996-11-13 Verwendung von magnetischer kernresonanz zur identifizierung von liganden für zielbiomoleküle Expired - Lifetime DE69606324T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US555691 1995-11-14
US08/555,691 US5698401A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to identify ligands to target biomolecules
PCT/US1996/018270 WO1997018471A1 (en) 1995-11-14 1996-11-13 Use of nuclear magnetic resonance to identify ligands to target biomolecules

Publications (3)

Publication Number Publication Date
DE69606324D1 DE69606324D1 (de) 2000-02-24
DE69606324T2 true DE69606324T2 (de) 2000-07-06
DE69606324T3 DE69606324T3 (de) 2008-02-07

Family

ID=24218250

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69631842T Expired - Lifetime DE69631842D1 (de) 1995-11-14 1996-11-13 Verfahren zum Entwerfen und Herstellung von zielmolekulbindenden Liganden
DE69606324T Expired - Lifetime DE69606324T3 (de) 1995-11-14 1996-11-13 Verwendung von magnetischer kernresonanz zur identifizierung von liganden für zielbiomoleküle

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69631842T Expired - Lifetime DE69631842D1 (de) 1995-11-14 1996-11-13 Verfahren zum Entwerfen und Herstellung von zielmolekulbindenden Liganden

Country Status (13)

Country Link
US (2) US5698401A (de)
EP (2) EP0981049B1 (de)
JP (1) JP3032301B2 (de)
AT (2) ATE189063T1 (de)
AU (1) AU701810B2 (de)
CA (1) CA2237343C (de)
DE (2) DE69631842D1 (de)
DK (1) DK0866967T4 (de)
ES (1) ES2143793T5 (de)
GR (1) GR3032361T3 (de)
IL (2) IL123923A (de)
PT (1) PT866967E (de)
WO (1) WO1997018471A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144661A1 (de) * 2001-09-11 2003-04-10 Forschungsverbund Berlin Ev Vorrichtung und Verfahren zur Zuordnung der NMR-Signale von Polypeptiden

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989827A (en) * 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
AU2426697A (en) * 1996-03-29 1997-10-22 Lawrence Berkeley National Laboratory Enhancement of nmr and mri in the presence of hyperpolarized noble gases
DE19649359C1 (de) * 1996-11-28 1998-02-12 Thomas Prof Dr Peters Verfahren zum Nachweis biologisch aktiver Substanzen in Substanzbibliotheken
US6043024A (en) * 1997-04-18 2000-03-28 Abbott Laboratories Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
AU772620B2 (en) * 1997-04-18 2004-05-06 Abbvie Inc. Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
US20030143757A1 (en) * 1997-06-13 2003-07-31 Jonathan Moore Methods for identifying drug cores
WO1998057155A1 (en) * 1997-06-13 1998-12-17 Vertex Pharmaceuticals Incorporated Methods for identifying drug cores
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
US6288234B1 (en) * 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US7501236B1 (en) * 1998-12-30 2009-03-10 Ge Healthcare Limited NMR spectroscopic in vitro assay using hyperpolarization
TWI283659B (en) * 1999-04-09 2007-07-11 Abbott Lab Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6897337B2 (en) * 1999-04-09 2005-05-24 Abbott Laboratories Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6333149B1 (en) 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6171804B1 (en) 1999-07-12 2001-01-09 The Rockefeller University Method of determining interdomain orientation and changes of interdomain orientation on ligation
US7105310B1 (en) * 2000-07-19 2006-09-12 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
AU6115300A (en) * 1999-07-19 2001-02-05 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
EP1212616A2 (de) * 1999-08-23 2002-06-12 Polaris Pharmaceuticals, Inc. Inhibitoren der bindung zwischen proteinen und makromolekularen liganden
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
DE60042658D1 (de) * 1999-09-29 2009-09-10 Nerviano Medical Sciences Srl Verfahren zur herstellung einer verbindungsbibliothek und identifizierung von lead chemischen templaten und liganden von zielmolekülen
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
WO2001023889A1 (en) * 1999-09-29 2001-04-05 Smithkline Beecham Corporation Method of using one-dimensional and multi-dimensional nuclear magnetic resonance to identify compounds that interact with target biomolecules
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
MXPA02008253A (es) * 2000-02-25 2002-11-29 Wyeth Corp Metodos de diseno de farmacos basados en la estructura usando em/rmn.
WO2001079852A2 (en) * 2000-04-17 2001-10-25 Pharmacia & Upjohn Company Nmr-methods for indentifying sites in papillomavirus e2 protein
GB0013115D0 (en) * 2000-05-31 2000-07-19 Imp College Innovations Ltd Biological materials and methods for use in the prevention or treatment of infections
US7146277B2 (en) * 2000-06-13 2006-12-05 James H. Prestegard NMR assisted design of high affinity ligands for structurally uncharacterized proteins
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
EP2280272A1 (de) 2000-09-27 2011-02-02 Universiteit Leiden Verfahren zur Anwendung der Kernspinresonanz zur Entdeckung von Liganden oder als ein Werkzeug zum Aussieben von medizinisch wirksamen Substanzen
SE0003811D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Screening methods
CA2432924A1 (en) * 2000-12-21 2002-06-27 Triad Therapeutics, Inc. Sea-trosy and related methods
YU51803A (sh) * 2000-12-22 2006-05-25 Ortho Mc Neil Pharmaceutical Inc. Supstituisani derivati triazol diamina kao inhibitori kinaza
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
US7645569B2 (en) * 2001-01-26 2010-01-12 Board Of Regents, The University Of Texas System NMR detection of foreign PAS domain ligands
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
DE10119455B4 (de) * 2001-04-20 2010-12-16 Siemens Ag Verfahren zum Auswerten von Daten, die mittels der Magnetresonanztechnik erzeugt werden und spektroskopische Information beinhalten
PT2070939E (pt) 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
WO2002097450A2 (en) * 2001-05-30 2002-12-05 Triad Therapeutics, Inc. Nuclear magnetic resonance-docking of compounds
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
US7653490B2 (en) * 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
US7179450B2 (en) * 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
WO2003040400A2 (en) * 2001-11-06 2003-05-15 Message Pharmaceuticals, Inc. Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
DE10160177A1 (de) * 2001-12-07 2003-06-26 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden die an ein drug target binden mittels 1H,1H-Kernresonanzspektroskopie
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20030180797A1 (en) * 2002-03-20 2003-09-25 Lin Yu Identification of ligands for a receptor family and related methods
AU2003253589A1 (en) * 2002-03-26 2003-11-10 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
DE10221158A1 (de) * 2002-05-13 2004-02-19 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden, die an ein drug target binden, mittels heteronuklearer Kernresonanzspektroskopie
EP1551291A4 (de) * 2002-06-10 2007-11-28 Prospect Pharma Verfahren zur gewinnung von dynamischen und strukturellen daten in bezug auf proteine und protein/liganden-komplexe
WO2006078228A1 (en) * 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
AU2003272548A1 (en) * 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
US20040132102A1 (en) * 2002-10-29 2004-07-08 Maurizio Pellecchia Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy
NO20025738D0 (no) 2002-11-29 2002-11-29 Amersham Health As Metode
JP2007524374A (ja) * 2003-02-28 2007-08-30 プレキシコン，インコーポレーテッド Ｐｙｋ２結晶構造および使用
CA2559711C (en) * 2003-03-13 2012-07-10 Triad Therapeutics, Inc. Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes
JP2007521252A (ja) * 2003-04-11 2007-08-02 エスジーエックス ファーマシューティカルズ，インコーポレイティド 化合物ライブラリーおよび薬剤発見方法
WO2004095028A1 (ja) * 2003-04-23 2004-11-04 Olympus Corporation 受容体に結合可能な物質をスクリーニングする方法
JP2004331832A (ja) * 2003-05-08 2004-11-25 Ricoh Co Ltd Ｄｎａインク組成物とそれを用いた識別画像印刷体、及びインクジェット記録装置
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7255985B2 (en) * 2003-07-10 2007-08-14 Pfizer Italia S.R.L. Fluorine NMR spectroscopy for biochemical screening
WO2005028624A2 (en) * 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20070275442A1 (en) * 2003-10-07 2007-11-29 Prospect Pharma Side Chain Deuterated Amino Acids Methods Of Use
JP4192078B2 (ja) * 2003-11-26 2008-12-03 株式会社日立製作所 核磁気共鳴方法
US7904252B2 (en) * 2003-11-28 2011-03-08 Hitachi, Ltd. Method for measuring a structural change in a protein
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
US7771938B2 (en) 2004-09-20 2010-08-10 Wisconsin Alumni Research Foundation Nonlinear spectroscopic methods for identifying and characterizing molecular interactions
WO2006082963A1 (ja) * 2005-02-07 2006-08-10 Mitsubishi Chemical Corporation 標的分子とリガンドあるいはリガンド候補化合物との結合検出方法
US20090239760A1 (en) 2006-03-14 2009-09-24 University Of Basel Method for the Identification of New Leads for Drug Candidates
US8933209B2 (en) 2006-04-26 2015-01-13 Abbvie Inc. Dep2 and its uses in major depressive disorder and other related disorders
US7760342B2 (en) 2007-12-21 2010-07-20 Wisconsin Alumni Research Foundation Multidimensional spectrometer
US20140024123A1 (en) * 2011-02-07 2014-01-23 National University Corporation Kobe University Aqueous Solution Containing Partial Ras Polypeptide and Method for Screening Inhibitor of Ras Function
EP3272769B1 (de) 2012-01-26 2020-06-17 Christopher J. Soares Peptidantagonisten aus der calcitonin-cgrp-familie von peptidhormonen und deren verwendung
EP3334459A4 (de) 2015-08-11 2019-04-17 Arch Biopartners, Inc. Dpep-1-bindungszusammensetzungen und verfahren zur verwendung
EP3506925B1 (de) 2016-09-02 2023-09-06 Christopher J. Soares Verwendung von cgrp-rezeptor-antagonisten bei der behandlung des glaukoms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT65361A (en) * 1989-12-29 1994-05-02 Univ Technologies Int Method for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
US5164297A (en) * 1990-05-03 1992-11-17 Advanced Magnetics Inc. Solvent mediated relaxation assay system
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0593618B1 (de) * 1991-06-27 1998-04-22 Genelabs Technologies, Inc. Screeningtest für den nachweis von dna-bindenden molekülen
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144661A1 (de) * 2001-09-11 2003-04-10 Forschungsverbund Berlin Ev Vorrichtung und Verfahren zur Zuordnung der NMR-Signale von Polypeptiden
DE10144661C2 (de) * 2001-09-11 2003-08-14 Forschungsverbund Berlin Ev Vorrichtung und Verfahren zur Zuordnung der NMR-Signale von Polypeptiden

Also Published As

Publication number Publication date
ES2143793T3 (es) 2000-05-16
CA2237343A1 (en) 1997-05-22
GR3032361T3 (en) 2000-04-27
DK0866967T4 (da) 2007-12-10
ES2143793T5 (es) 2008-03-01
DE69606324D1 (de) 2000-02-24
PT866967E (pt) 2000-04-28
WO1997018471A1 (en) 1997-05-22
EP0981049B1 (de) 2004-03-10
MX9803810A (es) 1998-09-30
EP0866967B2 (de) 2007-08-08
JPH11513498A (ja) 1999-11-16
CA2237343C (en) 2009-01-20
IL155988A0 (en) 2003-12-23
EP0866967A1 (de) 1998-09-30
IL155988A (en) 2005-07-25
ATE261581T1 (de) 2004-03-15
DK0866967T3 (da) 2000-06-26
DE69631842D1 (de) 2004-04-15
AU701810B2 (en) 1999-02-04
JP3032301B2 (ja) 2000-04-17
ATE189063T1 (de) 2000-02-15
IL123923A (en) 2005-07-25
US5804390A (en) 1998-09-08
EP0866967B1 (de) 2000-01-19
DE69606324T3 (de) 2008-02-07
US5698401A (en) 1997-12-16
AU7732896A (en) 1997-06-05
EP0981049A1 (de) 2000-02-23

Similar Documents

Publication Publication Date Title
DE69606324T2 (de) Verwendung von kernspinresonanz zur auffindung von liganden für bindungsmoleküle
CA2653517A1 (en) Process of designing a drug
US6043024A (en) Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
EP0117019B1 (de) Immunoassay-Methoden unter Anwendung von Mustern für die Auffindung von löslichen Antigenen und Zelloberflächenantigenen
ATE201768T1 (de) Verwendung von kernspinresonanz zur bestimmung von liganden für zielbiomoleküle
WO1990010709A3 (en) Monoclonal antibodies for metallic cations on small molecules
CA2176053A1 (en) Method and Apparatus for Agglutination Immunoassay
JP2002540423A (ja) 分析システム
DE59007200D1 (de) Verfahren zur Bestimmung eines Analyten.
ATE256119T1 (de) Verfahren zum nachweis von einer zielsubstanz in einer probe mit hilfe von pyryliumverbindung
DE69628194D1 (de) Verfahren zum nachweis von verbindungen die bestimmte zielmoleküle binden
DE3882904D1 (de) Aus zwei verzahnungen bestehendes konjugat und verfahren zu seiner verwendung.
CA2274776A1 (en) Method for analyzing annexin v in urine and use thereof
Chait et al. Clinical analysis: a perspective on chromatographic and immunoassay technology
Juarez-Garcia et al. Combined Moessbauer and EPR studies of the S= 3 state of an exchange-coupled iron (III)-copper (II) complex: test for quantitative EPR analysis of integer spin systems
WO2003054532A3 (de) Verfahren zur auffindung von liganden die an ein drug target binden mittels 1h,1h-kernresonanzspektroskopie
CA2237336A1 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
ATE344437T1 (de) Verfahren zur filterung von messdaten eines magnetfeldsensors
AU2925002A (en) Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings